Urokinase-Type Plasminogen Activator System in Breast Cancer
Open Access
- 1 July 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (13) , 4563-4568
Abstract
The prognostic value of components of the urokinase-type plasminogen activator (uPA) system, its receptor uPAR (CD87), and plasminogen activator inhibitors PAI-1 and PAI-2 is well established. We studied the predictive value of these proteolytic factors by evaluating the association of their tumor expression level and the efficacy of tamoxifen therapy in patients with recurrent breast cancer. The antigen levels of the four factors were determined by ELISA in cytosols prepared from estrogen receptor-positive primary breast tumors of 691 hormone-naive breast cancer patients with recurrent disease and treated with tamoxifen as first-line systemic therapy. High tumor levels of uPA (P < 0.001), uPAR (P < 0.01), and PAI-1 (P = 0.01) were associated with a lower efficacy of tamoxifen therapy. In the multivariable analysis, uPA (P < 0.001) provided additional information independent of the traditional predictive factors to predict benefit from tamoxifen therapy. High levels of uPA, uPAR, and PAI-1 predicted a shorter progression-free survival (PFS) on tamoxifen in an analysis of the first 9 months of therapy. However in the analysis during the total follow-up period, high PAI-2 levels (P = 0.01) showed a longer response to tamoxifen. In conclusion, uPA, uPAR, and PAI-1, components of the urokinase system, are predictive for the efficacy of tamoxifen therapy in patients treated for recurrent breast cancer. Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system.Keywords
This publication has 47 references indexed in Scilit:
- Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumoursExpert Opinion on Biological Therapy, 2001
- Modulators of the urokinase-type plasminogen activation system for cancerExpert Opinion on Therapeutic Patents, 2000
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Urokinase-type-plasminogen-activator(UPA) production by human breast (myo)fibroblastsin vitro: Influence of transforming growth factor-β1 (TGFβ1) compared with factor(s) released by human epithelial-carcinoma cellsInternational Journal of Cancer, 1998
- The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancerEuropean Journal of Cancer, 1997
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI: Journal of the National Cancer Institute, 1996
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Plasminogen activator inhibitors: hormonally regulated serpinsMolecular and Cellular Endocrinology, 1990
- Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. workshop, held on 16–17 March, 1979, in the Netherlands Cancer InstituteEuropean Journal of Cancer (1965), 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958